ImmunoPrecise Antibodies (NASDAQ: IPA) is scheduled to reveal its financial results for the first quarter on Monday 16th September 2024. This disclosure will take place before market open, providing investors with significant information regarding the company's performance in the last three months period.
the firm is poised to announce an estimated $0.08 loss per share for the quarter, as predicted by financial experts on Wall Street. Additionally, the firm is expected to reveal a total revenue of $4.96 million for this period.
Projections for the company's annual performance have been shared by Wall Street analysts, with an estimated total revenue of $21.37 million. Furthermore, they are predicting loss of $0.25 per share for the full year.
The per-share loss of $0.1 was highlighted in the company's earnings report for the same quarter of the prior year. This notable figure was achieved due to the company's impressive total revenue of $4.26 million recorded during that specific period.
In addition, The firm will review the first quarter financial results on 16th September 2024 at 10:30 AM eastern time, in a conference call with public.
ImmunoPrecise Antibodies (IPA) closed Friday's regular trading session at $0.67, marking a 3.08 percent upturn, with a volume of 337.20 thousand shares.
